Tell us about yourself
Are you primarily a:
EDMONTON, AB – June 20, 2016 - PACE Media launch
Inflammatory Bowel Disease (IBD) clinic at the University of Alberta with Crohn’s and Colitis Canada have embarked on a monumental project to reduce chronic steroid use among Canadians living with Crohn’s disease and Ulcerative colitis.
The project is part of a new, unique, national Promoting Access and Care through Centres of Excellence (PACE) network which is the largest Canadian collaboration to improve care for Canadians with Crohn's disease and Ulcerative Colitis, two main forms of IBD.
Harvey Doerr (left), Chair, Board of Directors, Crohn's and Colitis Canada, with The Honourable Sarah Hoffman, Minister of Health of Alberta, patient Tiffany Cooper and Dr. Richard Fedorak, PACE lead at the University of Alberta have declared the creation of Canada’s unique national collaboration of Inflammatory Bowel Disease centres of Excellence
PACE unites leading Canadian researcher clinicians in order to combine areas of expertise. The centres in the PACE collaborative network are at University of Calgary, McMaster University in Hamilton, McGill University in Montreal, and the Mount Sinai Hospital in Toronto.
PACE will immediately elevate access to quality care, advance best practices, standardize delivery of care and reduce chronic steroid use. Together, the centres of excellence can improve patient outcomes and care for Canadians living with IBD.
PACE area of focus
Reducing chronic steroid use
Dr. Richard Fedorak is a recognized global expert in the IBD field leading the PACE centre in Edmonton, at the University of Alberta. He is a recipient of numerous awards, research fellowships and grants, He has an active basic gastrointestinal research laboratory in the area of mucosal immunology, inflammation, and membrane function and structure. In addition, he leads a large gastrointestinal disease clinical research group and several quality improvement initiatives. He has published over 400 peer-reviewed manuscripts and book chapters, produced two patents on colonic-specific drug delivery, and has lectured around the world.
Are you primarily a: